子宫动脉栓塞术与子宫肌瘤剔除术的成本效用分析:FEMME试验
基于FEMME随机对照试验的经济学评价,纳入254例希望避免子宫切除的症状性子宫肌瘤绝经前女性,比较子宫动脉栓塞术(UAE)与子宫肌瘤剔除术的成本效用。从英国NHS视角分析,2年时UAE平均成本更高(差£645;95%CI -1381至2580)且QALYs更低(差-0.09;95%CI -0.11至-0.04),4年结果相似,UAE被肌瘤剔除术支配。结论认为肌瘤剔除术具成本效用,但差异较小,应充分告知女性并允许选择。
要点
- UAE在2年和4年随访中成本更高且QALYs更低,被肌瘤剔除术支配。
- 成本与QALY差异较小,应充分告知女性并允许两种术式间选择。
- 敏感性分析结果与基础案例分析一致。
核心结论
- 肌瘤剔除术是治疗子宫肌瘤具有成本效用的选择。
- UAE与肌瘤剔除术的成本和QALY差异较小,应充分告知女性并允许选择。
研究设计与样本
- 基于FEMME随机对照试验的经济学评价,从英国NHS视角进行试验内成本效用分析。
- 纳入254例希望避免子宫切除的症状性子宫肌瘤绝经前女性,随机分至UAE组(127例)和肌瘤剔除术组(127例)。
- 在2年和4年随访期内,使用EuroQoL EQ-5D-3L测量QALYs并结合成本评估成本效用。
主要发现
- 2年时UAE平均成本更高(差£645;95%CI -1381至2580)且QALYs更低(差-0.09;95%CI -0.11至-0.04)。
- 4年时结果相似,UAE被肌瘤剔除术支配。
- 敏感性分析结果与基础案例分析一致。
- 2年时UAE成本更高(差£456;95%CI -1823至3164)且QALYs更低(差-0.06;95%CI -0.11至-0.02)。
临床怎么用
- 临床决策中应将肌瘤剔除术作为具成本效用的选项告知希望避免子宫切除的症状性子宫肌瘤女性。
- 应充分告知女性UAE与肌瘤剔除术的成本和QALY差异较小,并允许其选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the cost-effectiveness of uterine artery embolisation (UAE) and myomectomy for women with symptomatic uterine fibroids wishing to avoid hysterectomy. DESIGN: Economic evaluation alongside the FEMME randomised controlled trial. SETTING: 29 UK hospitals. POPULATION: Premenopausal women who had symptomatic uterine fibroids amenable to UAE or myomectomy wishing to avoid hysterectomy. 254 women were randomised to UAE (127) and myomectomy (127). METHODS: A within-trial cost-utility analysis was conducted from the perspective of the UK NHS. MAIN OUTCOME MEASURES: Quality-adjusted life years (QALYs) measured using the EuroQoL EQ-5D-3L, combined with costs to estimate cost-effectiveness over 2 and 4 years of follow-up. RESULTS: Over a 2-year time horizon, UAE was associated with higher mean costs (difference £645; 95% CI -1381 to 2580) and lower QALYs (difference -0.09; 95% CI -0.11 to -0.04) when compared with myomectomy. Similar results were observed over the 4-year time horizon. Thus, UAE was dominated by myomectomy. Results of the sensitivity analyses were consistent with the base case results for both years. Over 2 years, UAE was associated with higher costs (difference £456; 95% CI -1823 to 3164) and lower QALYs (difference -0.06; 95% CI -0.11 to -0.02). CONCLUSIONS: Myomectomy is a cost-effective option for the treatment of uterine fibroids. The differences in costs and QALYs are small. Women should be fully informed and have the option to choose between the two procedures. TWEETABLE ABSTRACT: Fully informed women with uterine fibroids should have a choice between uterine artery embolisation or myomectomy.
引用
- Rana D, Wu O, Cheed V, et al. Uterine artery embolisation or myomectomy for women with uterine fibroids wishing to avoid hysterectomy: a cost-utility analysis of the FEMME trial. BJOG. 2021. PMID: 34053154. doi:10.1111/1471-0528.16781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。